TELO — Telo Genomics Share Price
0.000.00%
Last trade - 00:00- CA$14.17m
- CA$13.48m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 23.63 | ||
| Price to Tang. Book | 24.29 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -495.6% | ||
| Return on Equity | -419.51% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 30th Jun | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CA$m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Telo Genomics Corp. is a biotech company pioneering the telomere platform in the industry with applications and prognostic solutions. These include liquid biopsies and related technologies in oncology and neurological diseases. The Company's lead application, TELO-MM is being developed to provide actionable information to medical professionals in the treatment of multiple myeloma, a form of blood cancer. Its clinical studies and product development design includes TeloView SMM, TeloView Test to Predict Patient Resistance to Treatment, development in collaboration with the Mayo Clinic and TeloView Test to monitor minimal residual disease in MM patients. The Company, by combining quantitative analysis of three-dimensional telomeres with molecular biology and artificial intelligence to recognize disease associated genetic instability, is developing products that improve day-to-day care for patients by serving the needs of pathologists, clinicians, academic researchers and drug developers.
Directors
- Guido Baechler CHM
- Sherif Louis PRE
- Christopher Ross CFO
- Ryan Cheung DRC
- Sabine Mai DRC
- John Meekison IND
- Hugh Rogers IND
- Last Annual
- June 30th, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- May 25th, 2011
- Public Since
- February 15th, 2012
- No. of Employees
- 8
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- TSX Venture Exchange
- Shares in Issue
- 74,559,933
- Address
- Mars Centre, 101 College St Suite 200, TORONTO, M5G 1L7
- Web
- https://www.telodx.com/
- Phone
- +1 4166738487
- Contact
- Sherif Louis
- Auditors
- Smythe LLP
Upcoming Events for TELO
Q1 2025 Telo Genomics Corp Earnings Release
Telo Genomics Corp Annual Shareholders Meeting
Q2 2025 Telo Genomics Corp Earnings Release
Similar to TELO
Covalon Technologies
TSX Venture Exchange
Hemostemix
TSX Venture Exchange
Innovotech
TSX Venture Exchange
Kane Biotech
TSX Venture Exchange
KDA
TSX Venture Exchange
FAQ
What is the Telo Genomics share price?
As of Today at 23:38 UTC, shares in Telo Genomics are trading at CA$0.19. This share price information is delayed by 15 minutes.
How has the Telo Genomics share price performed this year?
Shares in Telo Genomics last closed at CA$0.19 and the price had moved by -34.48% over the past 365 days. In terms of relative price strength the Telo Genomics share price has underperformed the Toronto Stock Exchange 300 Composite Index by -42.27% over the past year.
What are the analyst and broker recommendations for Telo Genomics?
There is no consensus recommendation for this security.
Find out moreWhat is the Telo Genomics dividend yield?
Telo Genomics does not currently pay a dividend.
Does Telo Genomics pay a dividend?
Telo Genomics does not currently pay a dividend.
When does Telo Genomics next pay dividends?
Telo Genomics does not currently pay a dividend.
How do I buy Telo Genomics shares?
To buy shares in Telo Genomics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Telo Genomics?
As of the previous close price of CA$0.19, shares in Telo Genomics had a market capitalisation of CA$14.17m.
Where are Telo Genomics shares listed?
Here are the trading details for Telo Genomics:
- Country of listing: Canada
- Exchange: CVE
- Ticker Symbol: TELO
What kind of share is Telo Genomics?
Based on an overall assessment of its quality, value and momentum Telo Genomics is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Telo Genomics share price forecast for 2024?
We could not find analyst target price data for this security.
Find out moreWhat is the trend in the Telo Genomics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Telo Genomics. Over the past six months, its share price has outperformed the Toronto Stock Exchange 300 Composite Index by +29.68%.
As of the last closing price of CA$0.19, shares in Telo Genomics were trading +4.83% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Telo Genomics PE Ratio?
The Telo Genomics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at CA$0.19.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Telo Genomics?
Telo Genomics' management team is headed by:
- Guido Baechler - CHM
- Sherif Louis - PRE
- Christopher Ross - CFO
- Ryan Cheung - DRC
- Sabine Mai - DRC
- John Meekison - IND
- Hugh Rogers - IND